Does WellCare Cover Prolia?

How WellCare Classifies Prolia on Its Formularies

WellCare, now operating under Centene Corporation, administers Medicare Advantage (MA), Medicare Part D, and Medicaid managed-care plans across dozens of states. Prolia's placement on these formularies determines your copay, prior authorization burden, and step-therapy requirements.

Medicare Part B vs. Part D Coverage

Prolia is a physician-administered injectable, so it most commonly falls under Medicare Part B (the medical benefit) rather than Part D (the pharmacy benefit). When your doctor gives you the injection in the office, WellCare MA plans process the claim through Part B. You pay your plan's Part B cost-sharing, which is typically 20% of the Medicare-approved amount after the deductible [1]. The 2025 Medicare Part B deductible is $257 per year [2].

Medicaid Managed-Care Formulary Placement

On WellCare Medicaid plans, Prolia is classified as a specialty-tier drug subject to clinical review. Medicaid programs in most states cover Prolia when federal rebate agreements apply, but each state's preferred drug list dictates whether step therapy with a generic bisphosphonate is mandatory before approval [3]. States like Florida, Georgia, and Texas, where WellCare has large Medicaid enrollment, each maintain separate prior authorization criteria.

Prior Authorization Requirements for Prolia Under WellCare

Nearly every WellCare plan requires prior authorization (PA) before approving Prolia. The PA process confirms that the drug is medically necessary for your specific diagnosis and that you meet the plan's clinical criteria.

What WellCare Typically Requires

A standard WellCare PA request for Prolia asks for three things: a confirmed diagnosis of osteoporosis (T-score of -2.5 or below on dual-energy X-ray absorptiometry), documentation of fracture risk, and evidence that an oral bisphosphonate was tried, failed, or is contraindicated [4]. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend denosumab as a first-line option for patients at very high fracture risk, defined as a recent fracture within 12 months, T-score below -3.0, or a FRAX 10-year major osteoporotic fracture probability above 30% [5].

Turnaround Time and Approval Duration

WellCare must respond to a standard PA within 72 hours for Medicare plans and within the timeframe set by each state's Medicaid rules (often 24 to 72 hours for urgent requests). Approvals typically last 12 months, covering two injections. You will need to reauthorize annually.

Contraindications That Bypass Step Therapy

If you cannot tolerate oral bisphosphonates due to esophageal disorders, renal impairment with an eGFR below 30 to 35 mL/min, or documented gastrointestinal adverse events, WellCare may waive the step-therapy requirement. The FDA prescribing information for Prolia notes that denosumab does not require renal dose adjustment, making it a preferred choice when bisphosphonates are contraindicated by kidney function [6].

What Prolia Costs on a WellCare Plan

The wholesale acquisition cost of Prolia is approximately $1,824 per 60 mg prefilled syringe [7]. Your actual out-of-pocket expense depends on whether the claim processes through Part B, Part D, or Medicaid.

Part B Cost-Sharing

Under Medicare Part B, after you meet the annual deductible, WellCare MA plans generally charge 20% coinsurance for provider-administered drugs. For a single Prolia injection at the Medicare-approved rate, that could mean roughly $100 to $200 per dose before any supplemental coverage or plan-specific caps apply. Some WellCare MA plans offer $0 copays for Part B drugs after the deductible is met. Check your plan's Evidence of Coverage (EOC) document.

Part D Specialty Tier

When Prolia is dispensed through a specialty pharmacy (less common), it sits on the specialty tier. In the catastrophic coverage phase, Medicare Part D limits your cost to the greater of 5% coinsurance or $4.50/$11.20 per prescription in 2025 [2]. The Inflation Reduction Act's $2,000 annual out-of-pocket cap, fully effective in 2025, protects WellCare Part D enrollees from higher cumulative spending [8].

Amgen's ENBREL/Prolia Co-Pay Assistance

Amgen offers a patient assistance program and a co-pay card for commercially insured patients, but these programs do not apply to Medicare or Medicaid beneficiaries. Medicare enrollees on WellCare should instead explore State Pharmaceutical Assistance Programs (SPAPs) or the Medicare Extra Help/Low-Income Subsidy (LIS) program, which can reduce Part D costs to $0 to $11.20 per prescription [2].

Clinical Evidence Behind Prolia Coverage Decisions

Insurance coverage criteria, including WellCare's, are built around the clinical trial data supporting Prolia's efficacy and safety in osteoporosis populations.

The FREEDOM Trial

The key FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 3 years compared with placebo in postmenopausal women with osteoporosis [9]. This trial provided the primary efficacy data the FDA used for approval and that payers reference in coverage policies.

Long-Term Extension Data

The FREEDOM Extension study followed 4,550 women for up to 10 years of continuous denosumab use. Fracture incidence remained low: the rate of new vertebral fractures was 0.90% to 1.86% per year during years 4 through 10, and bone mineral density at the lumbar spine increased by a cumulative 21.7% from baseline [10]. Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, noted: "Ten years of denosumab therapy was associated with low fracture rates and continued increases in bone density without plateau, suggesting sustained skeletal benefit with ongoing treatment" [10].

Discontinuation Risk

One clinical factor that affects coverage decisions is the rebound vertebral fracture risk after stopping Prolia. A post hoc analysis of the FREEDOM trial found that vertebral fracture rates increased to 7.1% within 1 to 2 years of discontinuation, compared with 3% to 5% among patients who never received denosumab [11]. The AACE and the Endocrine Society both recommend transitioning to a bisphosphonate (typically zoledronic acid) after stopping denosumab to prevent this rebound effect [5][12]. The Endocrine Society's 2019 guideline states: "We recommend treatment with a potent antiresorptive agent, ideally a bisphosphonate, after discontinuation of denosumab to prevent the rapid bone loss and increased vertebral fracture risk observed following cessation" [12].

How to Get Prolia Approved Through WellCare

If your provider recommends Prolia, a structured approach to the PA request improves approval odds.

Step 1: Confirm Your Plan's Benefit Structure

Call the number on the back of your WellCare member ID card or log in to the member portal. Ask whether Prolia is covered under Part B (medical benefit) or Part D (pharmacy benefit) on your specific plan. This determines which PA form your provider needs to complete.

Step 2: Gather Documentation

Your provider should prepare a recent DXA scan showing a T-score of -2.5 or below (or -1.0 to -2.5 with high FRAX score), records of prior bisphosphonate use (drug name, dates, reason for discontinuation), and any relevant fracture history. For glucocorticoid-induced osteoporosis, documentation of prednisone-equivalent doses of 7.5 mg/day or higher for 3 months or longer is standard [13].

Step 3: Submit and Track

Your provider's office submits the PA through WellCare's electronic portal or by fax. Track the request through your member account. If no response arrives within 72 hours for Medicare or the applicable state deadline for Medicaid, contact WellCare member services to escalate.

What to Do if WellCare Denies Prolia Coverage

Denials happen. They are not final.

Internal Appeal

You have 60 days from the denial notice to file a standard internal appeal with WellCare. Include a letter of medical necessity from your provider explaining why Prolia is the appropriate treatment, why alternatives are unsuitable, and citing guideline recommendations from AACE or the Endocrine Society [5][12]. WellCare must decide standard appeals within 30 days for Medicare Part C and 7 days for expedited requests.

External Review and Medicare Redetermination

If WellCare upholds the denial on appeal, Medicare beneficiaries can request an independent review through a Qualified Independent Contractor (QIC). Medicaid enrollees may request a state fair hearing. Success rates for Part B drug appeals vary, but CMS data from 2023 showed that approximately 75% of Medicare Advantage appeals that reached the independent review level were decided at least partially in favor of the enrollee [14].

Alternative Coverage Pathways

If coverage is denied and appeals are exhausted, ask your provider about zoledronic acid (Reclast), a once-yearly IV bisphosphonate that WellCare generally covers under Part B with fewer PA hurdles. Oral bisphosphonates (alendronate, risedronate) are generic and sit on lower formulary tiers with minimal or no PA requirements.

WellCare Coverage for Other Prolia Indications

Prolia carries FDA approval beyond postmenopausal osteoporosis, and WellCare coverage criteria differ by indication.

Glucocorticoid-Induced Osteoporosis

WellCare covers Prolia for GIO in patients on chronic glucocorticoids at high fracture risk. The PA criteria typically mirror the ACR 2022 guidelines, which conditionally recommend denosumab for adults aged 40 and older on prednisone-equivalent doses of 2.5 mg/day or higher who are at moderate-to-high fracture risk [13].

Bone Loss From Hormone Ablation Therapy

Men receiving androgen-deprivation therapy for prostate cancer and women on aromatase inhibitors for breast cancer may qualify for Prolia coverage under WellCare. The HALT trial (N=1,468) showed that denosumab increased lumbar spine BMD by 5.6% at 24 months in men on ADT, compared with a 1.0% loss with placebo [15]. PA requirements for this indication include documentation of the cancer diagnosis, current hormone therapy, and a DXA scan.

Xgeva vs. Prolia Distinction

Denosumab is marketed as Xgeva (120 mg) for skeletal events in metastatic cancer and as Prolia (60 mg) for osteoporosis. These are billed under different codes. If your provider submits a Prolia claim for a bone-metastasis indication or vice versa, WellCare will deny it. Confirm the correct product and billing code (J0897 for Prolia, J0178 for Xgeva) before submission.

Monitoring and Follow-Up While on Prolia

WellCare's coverage of ongoing Prolia injections assumes adherence to standard monitoring. Missing your 6-month injection window by more than a few weeks raises discontinuation-related fracture risk.

Recommended Labs and Imaging

The Endocrine Society recommends checking serum calcium and 25-hydroxyvitamin D before initiating denosumab and supplementing as needed [12]. Repeat DXA scans every 1 to 2 years assess treatment response. WellCare covers DXA scans under Part B once every 24 months for most patients, or more frequently if medically justified [1].

Injection Scheduling

Prolia must be given every 6 months. Set your appointments at fixed 26-week intervals. If you switch WellCare plans during open enrollment, confirm that your new plan also covers Prolia and that PA transfers or new authorization is in place before your next scheduled dose. A gap in treatment after denosumab, even one missed dose, can trigger the rebound bone-loss phenomenon documented in the FREEDOM discontinuation analyses [11].